Evicenter
Ocrevus (ocrelizumab) in Multiple sclerosis
Manufacturer
Genentech, Inc.
Questions
60
Last updated

All questions

Clinical trials: Ocrevus (ocrelizumab) in multiple sclerosis

15 questions · 9 sources

Study results

How much does Ocrevus reduce MS relapses vs Rebif (OPERA I and II)?

Applies to Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

Note: The relapse-free proportions are from Table 6 of the OCREVUS Prescribing Information, in the order Study 1 OCREVUS, Study 1 REBIF, Study 2 OCREVUS, Study 2 REBIF; Studies 1 and 2 are OPERA I and II (same enrollment, 410 and 411, 417 and 418).

Does Ocrevus slow MS disability progression vs Rebif (OPERA I and II)?

Applies to Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

Note: The pooled 24-week CDP proportion for Rebif is given as 12% on the efficacy page and as 12.2% on the Why Ocrelizumab page of the same site.

Can Ocrevus improve disability (confirmed disability improvement) in relapsing MS?

Applies to Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

How much does Ocrevus reduce MS lesions on MRI compared with Rebif?

Applies to Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

Note: Both rows are from Table 6 of the OCREVUS Prescribing Information, in the order Study 1 OCREVUS, Study 1 REBIF, Study 2 OCREVUS, Study 2 REBIF, measured over 96 weeks; Studies 1 and 2 are OPERA I and II.

How many Ocrevus patients had no evidence of disease activity (OPERA I and II)?

Applies to Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

How well does Ocrevus work in primary progressive MS (ORATORIO)?

Applies to Primary progressive multiple sclerosis in adults (OCREVUS intravenous)

Note: Study 3 of the OCREVUS Prescribing Information is ORATORIO (488 OCREVUS, 244 placebo). In its Table 7 the first value is OCREVUS and the second placebo. In the PPMS brochure passage, the first hazard ratio is for 12-week CDP (primary endpoint) and the second for 24-week CDP. In the brochure figure, 24-week CDP occurred in 29.6% of ocrelizumab-treated and 35.7% of placebo-treated patients.

Does Ocrevus work differently in men and women with primary progressive MS?

Applies to Primary progressive multiple sclerosis in adults (OCREVUS intravenous)

Does Ocrevus slow disability in advanced primary progressive MS (OHAND)?

Applies to Primary progressive multiple sclerosis in adults (OCREVUS intravenous)

Note: In the brochure figure, 12-week cCDP occurred in 32.7% of ocrelizumab-treated patients (165) and 40.4% of placebo-treated patients (205); the extracted text lists the two values in reverse order. OHAND is not described in the OCREVUS Prescribing Information.

How was Ocrevus Zunovo compared with Ocrevus IV (OCARINA II)?

Applies to Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

Note: Study 4 of the OCREVUS ZUNOVO Prescribing Information is OCARINA II.

Does Ocrevus Zunovo deplete B cells as much as Ocrevus IV?

Applies to Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

How many patients on Ocrevus Zunovo stayed relapse-free (OCARINA II)?

Applies to Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

Note: OCARINA II was open label. The IV/SC arm received intravenous ocrelizumab for the first dose before OCREVUS ZUNOVO; the SC/SC arm received OCREVUS ZUNOVO throughout. On the efficacy page, the 97.2% values sit beneath a graphic of the proportion of patients free of relapses at Week 72.

How did Ocrevus work in Black and Hispanic people with MS (CHIMES study)?

Applies to Black and Hispanic adults with relapsing multiple sclerosis (OCREVUS intravenous, CHIMES)

Note: The three NEDA values at Week 48 are for all 182 patients, the 113 Black patients, and the 69 Hispanic patients.

Long-term data

What are the long-term results of Ocrevus in relapsing MS (10+ years)?

Applies to Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

Note: Year-by-year relapse and disability values from the extension appear on the page only as figures.

What are the long-term side effects of Ocrevus?

Applies to Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)

Note: The all-exposure population includes patients from the controlled trials, their open-label extensions, and other ocrelizumab studies.

Patient experience

Do patients prefer Ocrevus Zunovo injections or Ocrevus IV infusions?

Applies to Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)